What is Incyte Genomics Inc's earnings per share (EPS)?

Incyte Genomics Inc (INCY) reported diluted earnings per share of $6.41 for fiscal year 2025. This represents a 4173.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Incyte Genomics Inc (INCY) Financials

INCY

Trailing 12 months to March 31, 2026

Revenue $5.4B +21.5% YoY

Net Income $1.4B +6636.4% YoY

EPS (Diluted) $7.08 +2732.0% YoY

Operating Cash Flow $1.5B +296.4% YoY

Market Cap $23.0B as of Oct 7, 2026

Price / Sales 4.3x on $5.4B revenue, trailing 12 months to March 31, 2026

Price / Earnings 16.1x on $1.4B net income, trailing 12 months to March 31, 2026

Price / Book 4.1x on $5.6B equity, Q1 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Apr 28, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed Apr 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INCY SEC filings page.

Incyte Genomics Inc (INCY) reported $5.4B in revenue over the twelve months to Mar 31, 2026, up 21.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INCY FY2025 2026-10-03

Revenue growth returned with a dramatic operating-margin rebound after R&D spending compressed profits in FY2024.

The earnings rebound was driven below gross profit: gross margin barely changed from 92.6% in FY2024 to 92.8% in FY2025, while R&D declined from $2.6B to $2.1B. That pattern points to a sharp change in expense intensity rather than a fundamental shift in product-level economics.

Revenue moved from $4.2B in FY2024 to $5.1B in FY2025, but the more revealing change was operating income, which rose from $61M to $1.5B. Growth therefore converted into profit far more efficiently once R&D spending normalized.

FY2024 included $2.0B of share repurchases, while equity fell from $5.2B in FY2023 to $3.4B. By FY2025, equity had returned to $5.2B and the current ratio was 3.3x, while operating cash flow of $1.4B exceeded net income of $1.3B, indicating that the reported profit was broadly converting into cash.

Financial Health Signals

Financial Health Score 63/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Incyte Genomics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Incyte Genomics Inc has an operating margin of 29.5%, meaning the company retains $29 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is up from 1.5% the prior year.

Growth

Incyte Genomics Inc's revenue surged 21.2% year-over-year to $5.1B, reflecting rapid business expansion. This strong growth earns a score of 80/100.

Leverage

Incyte Genomics Inc carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.32, Incyte Genomics Inc holds $3.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.

Cash Flow

Not available for Incyte Genomics Inc, and counted as zero in the overall score.

Returns

Incyte Genomics Inc earns a strong 24.9% return on equity (ROE), meaning it generates $25 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 73/100. This is up from 0.9% the prior year.

Altman Z-Score Safe

9.81

Incyte Genomics Inc scores 9.81, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($23.0B) relative to total liabilities ($1.8B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Incyte Genomics Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.10x

For every $1 of reported earnings, Incyte Genomics Inc generates $1.10 in operating cash flow ($1.4B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

623.91x

Incyte Genomics Inc earns $623.91 in operating income for every $1 of interest expense ($1.5B vs $2.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.3B

YoY+20.9%

QoQ-15.5%

5Y CAGR+16.0%

10Y CAGR+17.1%

Incyte Genomics Inc generated $1.3B in revenue in Q1 2026. This represents an increase of 20.9% from the same quarter a year earlier. Against the prior quarter it is down 15.5%.

EBITDA

$324.9M

YoY+42.8%

QoQ-9.7%

5Y CAGR+23.6%

Incyte Genomics Inc's EBITDA was $324.9M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 42.8% from the same quarter a year earlier. Against the prior quarter it is down 9.7%.

Net Income

$303.3M

YoY+91.7%

QoQ+1.3%

5Y CAGR+41.5%

10Y CAGR+28.9%

Incyte Genomics Inc reported $303.3M in net income in Q1 2026. This represents an increase of 91.7% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

EPS (Diluted)

$1.47

YoY+83.7%

QoQ+0.7%

5Y CAGR+43.7%

10Y CAGR+28.5%

Incyte Genomics Inc earned $1.47 per diluted share (EPS) in Q1 2026. This represents an increase of 83.7% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Cash & Balance Sheet

Cash & Debt

$3.5B

YoY+78.2%

QoQ+11.7%

5Y CAGR+15.7%

10Y CAGR+18.1%

Incyte Genomics Inc held $3.5B in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

200M

YoY+3.2%

QoQ+0.4%

5Y CAGR-1.9%

10Y CAGR+0.6%

Incyte Genomics Inc had 200M shares outstanding in Q1 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

91.8%

YoY-1.3pp

QoQ-0.2pp

5Y change-3.4pp

Incyte Genomics Inc's gross margin was 91.8% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Operating Margin

23.7%

YoY+4.2pp

QoQ+1.4pp

5Y change+7.3pp

Incyte Genomics Inc's operating margin was 23.7% in Q1 2026, reflecting core business profitability. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.4 percentage points.

Net Margin

23.8%

YoY+8.8pp

QoQ+4.0pp

5Y change+15.0pp

10Y change+14.7pp

Incyte Genomics Inc's net profit margin was 23.8% in Q1 2026, showing the share of revenue converted to profit. This is up 8.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.

Return on Equity

5.4%

YoY+1.1pp

QoQ-0.4pp

5Y change+3.4pp

10Y change-5.2pp

Incyte Genomics Inc's ROE was 5.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.4 percentage points.

Capital Allocation

R&D Spending

$515.9M

YoY+18.0%

QoQ-15.6%

5Y CAGR+10.9%

Incyte Genomics Inc invested $515.9M in research and development in Q1 2026. This represents an increase of 18.0% from the same quarter a year earlier. Against the prior quarter it is down 15.6%.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

INCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$5.4B	$5.1B+21.2%	$4.2B+14.8%	$3.7B+8.9%	$3.4B+13.7%	$3.0B+12.0%	$2.7B+23.5%	$2.2B+14.7%	$1.9B+22.5%	$1.5B+38.9%	$1.1B+46.7%	$753.8M+47.4%	$511.5M+44.1%	$354.9M+19.5%	$297.1M+214.5%	$94.5M
Cost of Revenue	$403.5M	$372.1M+19.2%	$312.1M+22.4%	$255.0M+23.2%	$207.0M+37.1%	$151.0M+15.0%	$131.3M+14.9%	$114.2M+21.4%	$94.1M+18.4%	$79.5M+36.6%	$58.2M+115.7%	$27.0M+797.9%	$3.0M+376.8%	$630K+301.3%	$157K	N/A
Gross Profit	$5.0B	$4.8B+21.4%	$3.9B+14.2%	$3.4B+7.9%	$3.2B+12.4%	$2.8B+11.8%	$2.5B+24.0%	$2.0B+14.4%	$1.8B+22.7%	$1.5B+39.1%	$1.0B+44.1%	$726.8M+42.9%	$508.5M+43.5%	$354.3M+19.3%	$296.9M	N/A
R&D Expenses	$2.1B	$2.1B-21.4%	$2.6B+60.2%	$1.6B+2.6%	$1.6B+8.8%	$1.5B-34.2%	$2.2B+92.0%	$1.2B-3.7%	$1.2B-9.7%	$1.3B+127.9%	$581.9M+21.3%	$479.5M+38.0%	$347.5M+33.4%	$260.4M+23.8%	$210.4M+17.7%	$178.7M
SG&A Expenses	$1.4B	$1.4B+10.8%	$1.2B+7.5%	$1.2B+15.3%	$1.0B+35.5%	$739.6M+43.1%	$516.9M+10.3%	$468.7M+7.9%	$434.4M+18.6%	$366.3M+20.8%	$303.3M+54.2%	$196.6M+18.6%	$165.8M+50.7%	$110.0M+28.8%	$85.4M+46.6%	$58.2M
Operating Income	$1.6B	$1.5B+2368.6%	$61.4M-90.1%	$620.5M+7.1%	$579.4M-1.1%	$585.8M+322.2%	-$263.7M-165.6%	$402.0M+211.1%	$129.2M+153.1%	-$243.4M-267.9%	$145.0M+186.3%	$50.7M+1154.4%	-$4.8M+70.2%	-$16.1M-1502.6%	$1.1M+100.8%	-$143.2M
EBITDA	N/A	$1.6B+967.7%	$150.6M-78.6%	$703.2M+8.6%	$647.3M+0.6%	$643.6M+403.8%	-$211.9M-146.4%	$456.5M+147.9%	$184.2M+196.3%	-$191.2M-194.0%	$203.4M+112.9%	$95.5M+161.0%	$36.6M+179.4%	$13.1M-57.9%	$31.1M+126.8%	-$116.2M
Interest Expense	$2.3M	$2.4M+6.5%	$2.3M-10.6%	$2.6M-4.3%	$2.7M+39.7%	$1.9M-12.2%	$2.2M+17.2%	$1.9M+20.2%	$1.5M-77.6%	$6.9M-82.2%	$38.7M-15.0%	$45.6M-2.6%	$46.8M+21.2%	$38.7M-16.1%	$46.1M+5.1%	$43.8M
Income Tax	$342.1M	$377.8M+33.0%	$284.0M+20.0%	$236.6M+25.6%	$188.5M+149.8%	-$378.1M-695.7%	$63.5M+59.2%	$39.9M+581.3%	$5.9M+587.1%	$852K-73.2%	$3.2M+210.4%	$1.0M+1653.0%	-$66K-122.1%	$299K+71.8%	$174K	N/A
Net Income	$1.4B	$1.3B+3846.9%	$32.6M-94.5%	$597.6M+75.4%	$340.7M-64.1%	$948.6M+420.8%	-$295.7M-166.2%	$446.9M+308.2%	$109.5M+135.0%	-$313.1M-400.5%	$104.2M+1495.8%	$6.5M+113.5%	-$48.5M+41.7%	-$83.1M-87.6%	-$44.3M+76.2%	-$186.5M
EPS (Basic)	N/A	$6.59+4018.8%	$0.16-94.0%	$2.67+74.5%	$1.53-64.4%	$4.30+416.2%	-$1.36-165.4%	$2.08+300.0%	$0.52+134.0%	-$1.53-378.2%	$0.55+1275.0%	$0.04+113.8%	-$0.29+48.2%	-$0.56	N/A	N/A
EPS (Diluted)	$7.08	$6.41+4173.3%	$0.15-94.3%	$2.65+74.3%	$1.52-64.4%	$4.27+414.0%	-$1.36-166.3%	$2.05+302.0%	$0.51+133.3%	-$1.53-383.3%	$0.54+1700.0%	$0.03+110.3%	-$0.29+48.2%	-$0.56	N/A	N/A
Diluted Shares (Avg)	N/A	201M-4.7%	211M-6.8%	226M+0.9%	224M+0.8%	222M+1.8%	218M+0.2%	218M+0.9%	216M+5.4%	205M+5.4%	194M+3.6%	187M+11.5%	168M+13.2%	148M	N/A	125M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$1.3B+20.9%	$1.5B+27.8%	$1.4B+20.0%	$1.2B+16.5%	$1.1B+19.5%	$1.2B+16.3%	$1.1B+23.8%	$1.0B+9.3%
Cost of Revenue	$104.5M+42.8%	$121.2M+36.9%	$99.0M+15.1%	$78.8M+2.8%	$73.2M+20.1%	$88.5M+26.9%	$86.0M+43.1%	$76.6M+12.2%
Gross Profit	$1.2B+19.2%	$1.4B+27.1%	$1.3B+20.4%	$1.1B+17.5%	$979.7M+19.5%	$1.1B+15.5%	$1.1B+22.5%	$967.1M+9.1%
R&D Expenses	$515.9M+18.0%	$611.4M+31.2%	$506.6M-11.6%	$494.9M-56.5%	$437.3M+1.9%	$466.0M+4.8%	$573.2M+52.6%	$1.1B+184.1%
SG&A Expenses	$328.1M+0.7%	$390.4M+19.5%	$329.1M+6.4%	$331.0M+8.2%	$325.7M+8.5%	$326.7M+13.3%	$309.2M+15.4%	$306.0M+7.8%
Operating Income	$301.1M+46.8%	$335.9M+11.4%	$443.5M+203.6%	$530.3M+210.9%	$205.2M+123.3%	$301.5M+61.0%	$146.1M-32.0%	-$478.1M-346.7%
EBITDA	$324.9M+42.8%	$359.8M+11.0%	$467.5M+177.3%	$553.2M+221.3%	$227.5M+99.9%	$324.2M+55.1%	$168.6M-28.6%	-$456.1M-313.0%
Interest Expense	$569K-13.8%	$582K+38.9%	$592K-23.5%	$594K-9.6%	$660K+53.5%	$419K-47.9%	$774K+24.2%	$657K+0.3%
Income Tax	$40.3M-47.0%	$90.7M-19.4%	$58.1M+16.1%	$153.0M+179.1%	$76.0M+14.1%	$112.5M+61.0%	$50.1M-19.9%	$54.8M-26.0%
Net Income	$303.3M+91.7%	$299.3M+48.8%	$424.2M+298.4%	$405.0M+191.1%	$158.2M-6.7%	$201.2M+0.1%	$106.5M-37.8%	-$444.6M-318.4%
EPS (Basic)	$1.52+85.4%	$1.51+57.3%	$2.17+294.5%	$2.09+202.5%	$0.82+7.9%	$0.96+6.7%	$0.55-27.6%	-$2.04-324.2%
EPS (Diluted)	$1.47+83.7%	$1.46+53.7%	$2.11+290.7%	$2.04+200.0%	$0.80+6.7%	$0.95+6.7%	$0.54-28.9%	-$2.04-326.7%
Diluted Shares (Avg)	207M+4.4%	N/A	201M+2.9%	199M-8.9%	198M-12.8%	N/A	196M-13.4%	218M-3.3%

INCY Balance Sheet

INCY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$7.0B+27.8%	$5.4B-19.7%	$6.8B+16.1%	$5.8B+18.4%	$4.9B+38.5%	$3.6B+3.9%	$3.4B+29.5%	$2.6B+14.9%	$2.3B+40.5%	$1.6B+62.6%	$1.0B+26.5%	$796.5M+26.5%	$629.6M+90.5%	$330.4M+0.4%	$329.0M
Current Assets	$5.0B+55.1%	$3.2B-30.3%	$4.6B+13.5%	$4.1B+31.2%	$3.1B+32.2%	$2.4B-4.9%	$2.5B+35.4%	$1.8B+21.8%	$1.5B+51.4%	$994.2M+18.0%	$842.4M+24.0%	$679.6M+22.3%	$555.8M+79.6%	$309.5M-0.4%	$310.8M
Cash & Equivalents	$3.1B+83.5%	$1.7B-47.5%	$3.2B+8.9%	$3.0B+43.5%	$2.1B+36.0%	$1.5B-17.4%	$1.8B+57.4%	$1.2B+29.4%	$899.5M+37.9%	$652.3M+25.1%	$521.4M+15.3%	$452.3M-4.1%	$471.4M+110.4%	$224.1M-18.0%	$273.2M
Short-Term Investments	$482.8M+2.7%	$470.3M+6.2%	$442.7M+53.9%	$287.5M-1.1%	$290.8M+0.8%	$288.4M+1.2%	$284.9M+3.8%	$274.3M+1.6%	$270.1M+72.9%	$156.2M-16.2%	$186.3M+25.9%	$148.0M+293.8%	$37.6M+761.6%	$4.4M-1.6%	$4.4M
Inventory	$101.1M+71.7%	$58.9M-6.5%	$63.0M+50.0%	$42.0M+50.5%	$27.9M+69.9%	$16.4M+44.1%	$11.4M+63.6%	$7.0M+7.5%	$6.5M+57.9%	$4.1M+130.3%	$1.8M+398.0%	$358K-11.8%	$406K+46.0%	$278K	N/A
Accounts Receivable	$1.0B+20.1%	$853.2M+14.7%	$743.6M+15.3%	$644.9M+4.6%	$616.3M+27.9%	$482.0M+56.1%	$308.8M+0.4%	$307.6M+15.5%	$266.3M+79.0%	$148.8M+30.0%	$114.5M+97.6%	$57.9M+63.8%	$35.4M-50.1%	$71.0M+1006.0%	$6.4M
Long-Term Investments	$0	$0-100.0%	$187.7M+40.4%	$133.7M-39.6%	$221.3M-0.5%	$222.3M+66.3%	$133.7M+34.7%	$99.2M-26.2%	$134.4M+320.0%	$32.0M-9.3%	$35.2M	$0	$0	$0	$0
Goodwill	$133.0M-14.5%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.8B-10.3%	$2.0B+25.4%	$1.6B+8.3%	$1.5B+26.4%	$1.2B+22.5%	$949.6M+14.6%	$828.3M+15.1%	$719.8M+7.1%	$672.0M-44.9%	$1.2B+45.8%	$836.3M-4.8%	$878.1M+6.7%	$822.7M+62.8%	$505.4M-9.1%	$556.0M
Current Liabilities	$1.5B-7.7%	$1.6B+32.4%	$1.2B+7.2%	$1.2B+35.4%	$854.3M+35.3%	$631.2M+23.0%	$513.3M+20.7%	$425.3M+13.3%	$375.4M+37.3%	$273.5M+62.8%	$168.0M-24.0%	$221.1M+104.6%	$108.0M-20.6%	$136.1M+0.3%	$135.6M
Non-Current Liabilities	$275.3M-22.4%	$354.8M+0.8%	$351.9M+12.1%	$313.8M+1.5%	$309.0M-3.0%	$318.5M+1.1%	$315.0M+7.0%	$294.5M-0.7%	$296.6M-68.6%	$945.6M+41.5%	$668.3M+1.7%	$657.0M-8.1%	$714.6M+93.5%	$369.3M-12.2%	$420.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$26.8M-96.4%	$749.8M0.0%	$749.8M-10.8%	$840.9M-0.7%	$846.6M+106.5%	$410.0M+29.7%	$316.2M
Total Equity	$5.2B+49.9%	$3.4B-33.6%	$5.2B+18.8%	$4.4B+15.9%	$3.8B+44.4%	$2.6B+0.5%	$2.6B+34.9%	$1.9B+18.1%	$1.6B+288.7%	$419.5M+145.1%	$171.2M+309.7%	-$81.6M+57.7%	-$193.1M-10.4%	-$175.0M+23.0%	-$227.1M
Retained Earnings	$213.8M+119.9%	-$1.1B-768.9%	$160.4M+136.7%	-$437.2M+43.8%	-$777.9M+54.9%	-$1.7B-20.7%	-$1.4B+23.8%	-$1.9B+5.6%	-$2.0B-18.8%	-$1.7B+5.9%	-$1.8B+0.4%	-$1.8B-2.8%	-$1.7B-5.0%	-$1.7B-2.8%	-$1.6B

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$7.3B+27.7%	$7.0B+27.8%	$6.3B+26.3%	$5.8B+24.9%	$5.7B-19.4%	$5.4B-19.7%	$5.0B-21.5%	$4.7B-24.9%
Current Assets	$5.5B+56.4%	$5.0B+55.1%	$4.3B+52.3%	$3.6B+41.9%	$3.5B-27.7%	$3.2B-30.3%	$2.8B-36.2%	$2.6B-39.8%
Cash & Equivalents	$3.5B+78.2%	$3.1B+83.5%	$2.5B+88.3%	$2.0B+98.0%	$1.9B-42.0%	$1.7B-47.5%	$1.3B-59.6%	$987.3M-68.5%
Short-Term Investments	$554.7M+18.8%	$482.8M+2.7%	$474.8M+1.6%	$466.8M+1.0%	$466.9M-7.4%	$470.3M+6.2%	$467.2M+61.5%	$462.2M+58.2%
Inventory	$115.6M+80.7%	$101.1M+71.7%	$83.4M+18.5%	$83.4M-17.2%	$64.0M+0.5%	$58.9M-6.5%	$70.4M+23.2%	$100.7M+180.2%
Accounts Receivable	$1.1B+27.7%	$1.0B+20.1%	$895.9M+18.1%	$842.9M+14.1%	$823.1M+10.4%	$853.2M+14.7%	$758.5M+15.4%	$739.0M+15.8%
Long-Term Investments	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%
Goodwill	$133.0M-14.5%	$133.0M-14.5%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%	$155.6M0.0%
Total Liabilities	$1.7B-17.6%	$1.8B-10.3%	$1.7B-8.8%	$1.7B-0.9%	$2.1B+19.6%	$2.0B+25.4%	$1.8B+26.4%	$1.7B+13.4%
Current Liabilities	$1.5B-13.4%	$1.5B-7.7%	$1.3B-10.8%	$1.3B-4.4%	$1.7B+23.2%	$1.6B+32.4%	$1.5B+33.5%	$1.3B+19.5%
Non-Current Liabilities	$226.6M-37.3%	$275.3M-22.4%	$340.4M+0.3%	$371.8M+13.5%	$361.5M+4.8%	$354.8M+0.8%	$339.6M+2.2%	$327.7M-6.1%
Total Equity	$5.6B+53.3%	$5.2B+49.9%	$4.7B+46.7%	$4.2B+39.2%	$3.7B-32.0%	$3.4B-33.6%	$3.2B-35.7%	$3.0B-36.8%
Retained Earnings	$517.1M+156.5%	$213.8M+119.9%	-$85.5M+93.3%	-$509.7M+63.1%	-$914.7M-377.2%	-$1.1B-768.9%	-$1.3B-3030.9%	-$1.4B-551.3%

Not reported in any period shown, so not listed: Long-Term Debt.

INCY Cash Flow Statement

INCY quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.5B	$1.4B+321.5%	$335.3M-32.5%	$496.5M-48.8%	$969.9M+29.4%	$749.5M+701.5%	-$124.6M-117.5%	$710.7M+111.4%	$336.2M+461.6%	-$93.0M-130.5%	$304.8M+240.9%	$89.4M+240.5%	$26.3M+186.0%	$9.2M+109.7%	-$94.8M+41.4%	-$161.7M
Depreciation & Amortization	N/A	$93.3M+4.5%	$89.2M+8.0%	$82.7M+21.8%	$67.9M+17.3%	$57.8M+11.7%	$51.8M-5.0%	$54.5M-0.8%	$55.0M+5.3%	$52.2M-10.7%	$58.4M+30.2%	$44.9M+8.4%	$41.4M+41.8%	$29.2M-2.6%	$30.0M+11.1%	$27.0M
Stock-Based Compensation	N/A	$249.3M-6.3%	$266.1M+23.2%	$215.9M+14.6%	$188.4M+3.0%	$183.0M+2.9%	$177.9M+6.8%	$166.6M+12.4%	$148.2M+11.3%	$133.1M+38.3%	$96.2M+37.7%	$69.9M+12.4%	$62.2M+61.9%	$38.4M-0.2%	$38.5M+32.8%	$29.0M
Capital Expenditures	N/A	N/A	N/A	N/A	$77.8M-57.0%	$181.0M-3.4%	$187.4M+140.0%	$78.1M+6.2%	$73.5M-33.8%	$111.0M-7.7%	$120.3M+362.6%	$26.0M-6.7%	$27.9M+553.3%	$4.3M+50.3%	$2.8M-25.3%	$3.8M
Free Cash Flow	N/A	N/A	N/A	N/A	$892.1M+56.9%	$568.5M+282.2%	-$312.0M-149.3%	$632.6M+140.8%	$262.7M+228.8%	-$204.0M-210.6%	$184.5M+191.0%	$63.4M+4013.9%	-$1.6M-133.0%	$4.9M+105.0%	-$97.7M+41.0%	-$165.5M
Investing Cash Flow	-$191.9M	-$102.6M-165.1%	$157.5M+175.8%	-$207.7M-164.4%	-$78.5M+62.2%	-$207.7M+22.8%	-$269.0M-207.6%	-$87.5M-1.2%	-$86.4M+75.3%	-$350.0M-50.5%	-$232.5M-121.4%	-$105.0M	N/A	N/A	N/A	N/A
Financing Cash Flow	$198.5M	$101.0M+105.0%	-$2.0B-9991.1%	-$20.0M-2423.0%	-$794K-112.9%	$6.2M-91.4%	$71.7M+56.9%	$45.7M+211.9%	$14.7M-97.9%	$690.2M+1446.8%	$44.6M-47.3%	$84.7M	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$2.0B	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	$369.4M+38.8%	$543.3M+42.5%	$559.4M+79.9%	$44.7M+107.8%	$266.1M+21.6%	$381.2M+158.1%	$310.9M+110.3%	-$575.6M-287.8%
Depreciation & Amortization	$23.8M+6.4%	$24.0M+5.5%	$24.0M+6.7%	$22.9M+4.0%	$22.4M+1.9%	$22.7M+4.5%	$22.5M+5.3%	$22.0M+8.6%
Stock-Based Compensation	$64.1M+5.2%	N/A	$61.6M-20.9%	$64.6M+14.1%	$61.0M+2.0%	N/A	$77.9M+62.3%	$56.6M+3.9%
Investing Cash Flow	-$88.2M-8140.4%	-$37.4M-74.3%	-$47.4M-223.9%	-$18.9M-108.8%	$1.1M+101.5%	-$21.5M+86.1%	$38.3M+322.7%	$213.8M+2978.2%
Financing Cash Flow	$84.8M+769.2%	$137.7M+575.4%	-$12.8M+60.5%	-$11.2M+99.4%	-$12.7M-2.1%	$20.4M+5794.2%	-$32.4M+13.2%	-$2.0B-15620.5%
Share Buybacks	N/A	$0	$0-100.0%	N/A	N/A	$0	$103K	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

INCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	92.8%+0.1pp	92.6%-0.5pp	93.1%-0.8pp	93.9%-1.0pp	94.9%-0.1pp	95.1%+0.4pp	94.7%-0.3pp	95.0%+0.2pp	94.8%+0.1pp	94.7%-1.7pp	96.4%-3.0pp	99.4%-0.4pp	99.8%-0.1pp	100.0%	N/A
Operating Margin	29.5%+28.0pp	1.5%-15.3pp	16.8%-0.3pp	17.1%-2.6pp	19.6%+29.5pp	-9.9%-28.5pp	18.6%+11.8pp	6.9%+22.7pp	-15.8%-28.9pp	13.1%+6.4pp	6.7%+7.7pp	-0.9%+3.6pp	-4.5%-4.9pp	0.4%	-151.6%
Net Margin	25.0%+24.3pp	0.8%-15.4pp	16.2%+6.1pp	10.0%-21.7pp	31.8%+42.9pp	-11.1%-31.8pp	20.7%+14.9pp	5.8%+26.2pp	-20.4%-29.8pp	9.4%+8.6pp	0.9%+10.3pp	-9.5%+14.0pp	-23.4%-8.5pp	-14.9%	-197.5%
Return on Equity	24.9%+23.9pp	0.9%-10.6pp	11.5%+3.7pp	7.8%-17.4pp	25.2%+36.5pp	-11.3%-28.5pp	17.2%+11.5pp	5.7%+24.9pp	-19.2%-44.0pp	24.9%+21.0pp	3.8%	N/A	N/A	N/A	N/A
Return on Assets	18.5%+17.9pp	0.6%-8.2pp	8.8%+3.0pp	5.8%-13.4pp	19.2%+27.5pp	-8.3%-21.3pp	13.0%+8.9pp	4.1%+17.7pp	-13.6%-20.0pp	6.4%+5.7pp	0.7%+6.7pp	-6.1%+7.1pp	-13.2%+0.2pp	-13.4%+43.3pp	-56.7%
Current Ratio	3.32+1.3x	1.97-1.8x	3.75+0.2x	3.54-0.1x	3.65-0.1x	3.74-1.1x	4.83+0.5x	4.31+0.3x	4.01+0.4x	3.63-1.4x	5.01+1.9x	3.07-2.1x	5.14+2.9x	2.270.0x	2.29
Debt-to-Equity	0.35-0.2x	0.58+0.3x	0.310.0x	0.340.0x	0.31-0.1x	0.360.0x	0.32-0.1x	0.37+0.4x	0.02-1.8x	1.79-2.6x	4.38	N/A	N/A	N/A	N/A
Asset Turnover	0.740.0x	0.78+0.2x	0.540.0x	0.580.0x	0.61-0.1x	0.75+0.1x	0.63-0.1x	0.710.0x	0.670.0x	0.67-0.1x	0.75+0.1x	0.64+0.1x	0.56-0.3x	0.90+0.6x	0.29
FCF Margin	N/A	N/A	N/A	26.3%+7.2pp	19.0%+30.7pp	-11.7%-41.0pp	29.3%+15.3pp	14.0%+27.2pp	-13.3%-30.0pp	16.7%+8.3pp	8.4%+8.7pp	-0.3%-1.7pp	1.4%+34.3pp	-32.9%	-175.2%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Gross Margin	91.8%-1.3pp	92.0%-0.5pp	92.8%+0.3pp	93.5%+0.9pp	93.0%0.0pp	92.5%-0.6pp	92.4%-1.0pp	92.7%-0.2pp
Operating Margin	23.7%+4.2pp	22.3%-3.3pp	32.5%+19.6pp	43.6%+89.4pp	19.5%+9.1pp	25.6%+7.1pp	12.8%-10.5pp	-45.8%-66.1pp
Net Margin	23.8%+8.8pp	19.9%+2.8pp	31.1%+21.7pp	33.3%+75.9pp	15.0%-4.2pp	17.1%-2.8pp	9.4%-9.3pp	-42.6%-63.9pp
Return on Equity	5.4%+1.1pp	5.8%-0.1pp	9.1%+5.8pp	9.7%+24.5pp	4.3%+1.2pp	5.8%+2.0pp	3.4%-0.1pp	-14.8%-19.1pp
Return on Assets	4.1%+1.4pp	4.3%+0.6pp	6.7%+4.6pp	7.0%+16.5pp	2.8%+0.4pp	3.7%+0.7pp	2.1%-0.6pp	-9.5%-12.8pp
Current Ratio	3.68+1.6x	3.32+1.3x	3.20+1.3x	2.85+0.9x	2.04-1.4x	1.97-1.8x	1.87-2.0x	1.92-1.9x
Debt-to-Equity	0.31-0.3x	0.35-0.2x	0.36-0.2x	0.40-0.2x	0.57+0.2x	0.58+0.3x	0.58+0.3x	0.56+0.2x
Asset Turnover	0.170.0x	0.220.0x	0.220.0x	0.210.0x	0.18+0.1x	0.22+0.1x	0.23+0.1x	0.22+0.1x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Incyte Genomics Inc INCY	FY2025	$5.1B	$1.3B	25.0%	$23.0B	63/100
Genmab A/S GMAB	FY2025	$3.7B	$963.0M	25.9%	$23.2B	55/100
Summit Therapeutics Inc. SMMT	FY2025	N/A	-$1.1B	N/A	$13.8B	—
Royalty Pharma plc RPRX	FY2025	$2.4B	$770.9M	32.4%	$25.1B	44/100

Where Incyte Genomics Inc Ranks

Frequently Asked Questions

What is Incyte Genomics Inc's annual revenue?

Incyte Genomics Inc (INCY) reported $5.1B in total revenue for fiscal year 2025. This represents a 21.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Incyte Genomics Inc's revenue growing?

Incyte Genomics Inc (INCY) revenue grew by 21.2% year-over-year, from $4.2B to $5.1B in fiscal year 2025.

Is Incyte Genomics Inc profitable?

Yes, Incyte Genomics Inc (INCY) reported a net income of $1.3B in fiscal year 2025, with a net profit margin of 25.0%.

What is Incyte Genomics Inc's EBITDA?

Incyte Genomics Inc (INCY) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Incyte Genomics Inc's gross margin?

Incyte Genomics Inc (INCY) had a gross margin of 92.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Incyte Genomics Inc's operating margin?

Incyte Genomics Inc (INCY) had an operating margin of 29.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Incyte Genomics Inc's net profit margin?

Incyte Genomics Inc (INCY) had a net profit margin of 25.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Incyte Genomics Inc's return on equity (ROE)?

Incyte Genomics Inc (INCY) has a return on equity of 24.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Incyte Genomics Inc's operating cash flow?

Incyte Genomics Inc (INCY) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Incyte Genomics Inc's total assets?

Incyte Genomics Inc (INCY) had $7.0B in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Incyte Genomics Inc spend on research and development?

Incyte Genomics Inc (INCY) invested $2.1B in research and development during fiscal year 2025.

How many shares does Incyte Genomics Inc have outstanding?

Incyte Genomics Inc (INCY) had 199M shares outstanding as of fiscal year 2025.

What is Incyte Genomics Inc's current ratio?

Incyte Genomics Inc (INCY) had a current ratio of 3.32 as of fiscal year 2025, which is generally considered healthy.

What is Incyte Genomics Inc's debt-to-equity ratio?

Incyte Genomics Inc (INCY) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Incyte Genomics Inc's return on assets (ROA)?

Incyte Genomics Inc (INCY) had a return on assets of 18.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Incyte Genomics Inc's P/E ratio?

Incyte Genomics Inc (INCY) trades at 16.1x earnings, its market capitalization divided by net income of $1.4B net income, trailing 12 months to March 31, 2026. The market capitalization is $23.0B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Incyte Genomics Inc's price-to-sales ratio?

Incyte Genomics Inc (INCY) trades at 4.3x sales, its market capitalization divided by revenue of $5.4B revenue, trailing 12 months to March 31, 2026. The market capitalization is $23.0B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Incyte Genomics Inc's Altman Z-Score?

Incyte Genomics Inc (INCY) has an Altman Z-Score of 9.81, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Incyte Genomics Inc's Piotroski F-Score?

Incyte Genomics Inc (INCY) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Incyte Genomics Inc's earnings high quality?

Incyte Genomics Inc (INCY) has an earnings quality ratio of 1.10x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Incyte Genomics Inc cover its interest payments?

Incyte Genomics Inc (INCY) has an interest coverage ratio of 623.91x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Incyte Genomics Inc?

Incyte Genomics Inc (INCY) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.